Class summary at a glance.

Every drug in the Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $56.3Mcombined across class
Total Rx claims: 72755 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Elosulfase Alfa

Brand: VIMIZIM · 251 Part D claims (CY24) · 33 beneficiaries · First FDA approval: 2014-02-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $25.3M

Class share

45%

of class CY24 spend

View profile →

Laronidase

Brand: ALDURAZYME · 234 Part D claims (CY24) · 11 beneficiaries · First FDA approval: 2003-04-30

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $11.5M

Class share

20%

of class CY24 spend

View profile →

Idursulfase

Brand: ELAPRASE · 176 Part D claims (CY24) · 11 beneficiaries · First FDA approval: 2006-07-24

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $11.4M

Class share

20%

of class CY24 spend

View profile →

Galsulfase

Brand: NAGLAZYME · 66 Part D claims (CY24) · First FDA approval: 2005-06-09

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $8.1M

Class share

14%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.